ESR1 and breast carcinoma: Razavi et al. evaluated ctDNA in hormone receptor-positive breast cancer patients on a phase I/II trial of the PI3K-alpha inhibitor alpelisib given with an aromatase inhibitor and found that loss of function PTEN mutations and ESR1-activating mutations emerged with resistance [46].